Celularity Inc

Celularity Inc, the clinical-stage cell therapy company that became the de-SPAC merger target of GX Acquisition Corp. II (Nasdaq: GXGX), filed a Form 10-Q with the SEC on November 16, 2020, under accession number 0001213900-20-037167. GXGX, sponsored by GX Sponsor II LLC, completed its initial public offering in 2020 with a focus on the healthcare and biotechnology sector, specifically targeting opportunities in cell and gene therapy. Celularity, founded by Robert Hariri, develops placental-derived allogeneic cell therapies across oncology, infectious disease, and degenerative conditions. The quarterly filing captured the company's financial position during an active period in healthcare-focused SPAC activity. Sign up at SpacDesk for full filing history, deal timelines, and analytics on GXGX and thousands of other SPACs.